VC giant NEA backs an upstart’s plan to tackle neurodegeneration
Neurodegenerative diseases are both one of the toughest challenges in drug development as well as potentially one of the most lucrative fields in the business. If you can figure out what the bad players are that trigger damage, and come up with a drug to halt or even modestly slow that process, you could have a blockbuster on your hands.
But then there’s a long line of companies that have tried and failed at it, blowing billions in the process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
